Shilpa Medicare Ltd Share Price (SHILPAMED)

Shilpa Medicare Receives Regulatory Approvals for Meniere's Syndrome Drug - 04 Sep, 2023

Shilpa Medicare Ltd has received marketing authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, for Betahistine Dihydrochloride Orodispersible Films. The company also successfully completed an inspection by Japan’s Pharmaceuticals and Medical Devices Agency. Shilpa is the first company to receive approval for the 24 mg strength as a film formulation in the UK.

Shilpa Medicare Receives Approval for Pemetrexed Injections - 01 Aug, 2023

Shilpa Medicare Limited has received approval from CDSCO to manufacture and sell Pemetrexed Ready to Use injections in India under the brand name VRTU.

Shilpa Medicare's Balance Sheet Poses Risk to Business - 17 Jul, 2023

Shilpa Medicare Ltd has a net debt of about ₹7.74b, with liabilities totaling ₹7.75b more than its cash and short-term receivables. Shareholders face high net debt to EBITDA ratio (7.6) and weak interest coverage, making the debt burden substantial.

Shilpa Medicare Stock Surges on Positive News - 30 Jun, 2023

Shilpa Medicare Ltd's stock jumps 15.7% on high volumes as HNIs buy shares and anticipate a corporate development. Additionally, the company's subsidiary, Shilpa Biologicals, received marketing authorization for its Adalimumab injection.

Shilpa Medicare Ltd board to evaluate rights issue proposal - 21 Jun, 2023

Pharmaceutical company Shilpa Medicare is considering a rights issue of equity shares. The US FDA classified its Hyderabad unit as Voluntary Action Indicated (VAI) in late May, which is a relief for the company at a time when scrutiny from the US drug regulator is leading to delays in key launches for several pharmaceutical companies.

Shilpa Medicare Ltd stock jumps 13.56% amid heavy volumes - 20 Jun, 2023

Shares of Shilpa Medicare Ltd surged by 13.56% to hit a day high of Rs 272.95 over its previous close of Rs 240.35 amid heavy volumes. The company reported a net loss of Rs 8 crore in Q4 FY23, compared to a net profit of Rs 29.50 crore during the same period last year due to tax outflow. However, the stock has an average target price of Rs 292, suggesting a potential upside of 9.67%. Support on the counter could be seen at Rs 255.